Drug permeability in IBD tissues
Drug permeability of therapies intended for use in patients with IBD can be assessed in human fresh IBD tissues using our Ussing Chamber methodology. Where artificial permeability models often use Caco-2 cell lines, which don't reflect the normal expression of enzymes and transporters, we use human fresh gastrointestinal (GI) mucosa from IBD patients to determine drug bioavailability. If you are primarily interested in investigating ion channel function and drug metabolism across all patients, not only those with IBD, we can achieve this using GI tissues from healthy donors. Endpoints that can be measured in this translational model include: